All News Prescient Therapeutics Limited

Equities

PTX

AU000000PTX3

Market Closed - Australian S.E. Other stock markets 06:59:24 17/05/2024 BST			5-day change	1st Jan Change
0.043 ^AUD	-2.27%		0.00%	-30.65%

03-25	Transcript : Prescient Therapeutics Limited - Special Call
02-23	Prescient Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2023	CI

All News

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Transcript : Prescient Therapeutics Limited - Special Call	03-24
Prescient Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2023	02-22	CI
Prescient Therapeutics Receives AU$2.4 Million R&D Tax Rebate; Shares Down 4%	11-28	MT
Prescient Therapeutics Limited Reports Earnings Results for the Full Year Ended June 30, 2023	25/08/23	CI
Prescient Therapeutics showcases cell therapy data at prestigious ISCT conference	16/06/23	AQ
Prescient Therapeutics Limited Appoints Ellen Feigal to the Board as Non- Executive Director	15/05/23	CI
Prescient Therapeutics Limited Provides an Update on the PTX-100 Phase 1b Expansion Cohort in Relapsed and Refractory T Cell Lymphomas	15/03/23	CI
Prescient Therapeutics thrilled with additional Orphan Drug Designation status for PTX-100	09/03/23	AQ
Prescient Therapeutics Secures US FDA Orphan Drug Designation for Lymphoma Medication; Shares Surge 29%	09/03/23	MT
Prescient Therapeutics Announces FDA Grants Broader Orphan Drug Status to PTX-100 for TCL Indications	08/03/23	CI
Prescient Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2022	24/02/23	CI
Prescient Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2022	24/02/23	CI
Transcript : Prescient Therapeutics Limited - Shareholder/Analyst Call	29/11/22
Prescient Therapeutics Sees Positive Results in PTX-100 Study	26/10/22	MT
Prescient Therapeutics Limited Announces PTX-100 Trial Update	24/10/22	CI
Prescient Therapeutics Unveils Cancer Drug CellPryme-A; Shares Rise 3%	23/09/22	MT
Prescient Therapeutics Unveils CellPryme-A to Boost Car-T Performance	22/09/22	CI
Transcript : Prescient Therapeutics Limited - Special Call	08/09/22
Prescient Therapeutics, MD Anderson Cancer Center to Develop Blood Cancer Binder for OmniCAR; Shares Rise 3%	07/09/22	MT
Transcript : Prescient Therapeutics Limited - Special Call	07/09/22

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News Prescient Therapeutics Limited

Equities

PTX

AU000000PTX3

All News

Filters